Trial · NCT00802100

Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia

NCT00802100, Phase 4, Completed, National Institute of Mental Health (NIMH); results first posted 2013-02-08

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia. Trials, record NCT00802100. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00802100

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia
NCT number: NCT00802100
Status: Completed
Phases: Phase 4
Enrollment: 21 participants, actual
Lead sponsor: National Institute of Mental Health (NIMH)
Conditions: Schizophrenia
Interventions: Olanzapine, Perphenazine, Aripiprazole, Metformin, Simvastatin, Benztropine
First posted: 2008-12-04
Last updated: 2013-02-08
Results first posted: 2013-02-08
Limitations and caveats: It was determined in this pilot study that the existing procedures and eligibility criteria could not be adequately implemented and that a larger-scale study was not feasible.

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Feasibility of Randomizing a Cohort of Participants Meeting the Inclusion and Exclusion Criteria of the Study	Baseline	Goal was to randomize 60 participants who met eligibility criteria.
Secondary	Antipsychotic Efficacy, Defined as Completion of the Trial Without Psychiatric Hospitalization, Clinician Decision to Discontinue Treatment, or Patient Decision to Discontinue Treatment	Measured over 28 weeks of study visits

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Feasibility of Randomizing a Cohort of Participants Meeting the Inclusion and Exclusion Criteria of the Study	Baseline	Total study population	participants	NUMBER
SECONDARY	Antipsychotic Efficacy, Defined as Completion of the Trial Without Psychiatric Hospitalization, Clinician Decision to Discontinue Treatment, or Patient Decision to Discontinue Treatment	Measured over 28 weeks of study visits	Analysis population is those randomized. Outcome is discontinuation from study treatment before 28 weeks	participants	NUMBER

Source ClinicalTrials.gov

Results by group19

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Feasibility of Randomizing a Cohort of Participants Meeting the Inclusion and Exclusion Criteria of the Study	Overall Study		21	participants
Antipsychotic Efficacy, Defined as Completion of the Trial Without Psychiatric Hospitalization, Clinician Decision to Discontinue Treatment, or Patient Decision to Discontinue Treatment	Olanzapine	Inefficacy	0	participants
Antipsychotic Efficacy, Defined as Completion of the Trial Without Psychiatric Hospitalization, Clinician Decision to Discontinue Treatment, or Patient Decision to Discontinue Treatment	Perphenazine	Inefficacy	1	participants
Antipsychotic Efficacy, Defined as Completion of the Trial Without Psychiatric Hospitalization, Clinician Decision to Discontinue Treatment, or Patient Decision to Discontinue Treatment	Aripiprazole	Inefficacy	1	participants
Antipsychotic Efficacy, Defined as Completion of the Trial Without Psychiatric Hospitalization, Clinician Decision to Discontinue Treatment, or Patient Decision to Discontinue Treatment	Olanzapine	Unacceptable side effects	0	participants
Antipsychotic Efficacy, Defined as Completion of the Trial Without Psychiatric Hospitalization, Clinician Decision to Discontinue Treatment, or Patient Decision to Discontinue Treatment	Perphenazine	Unacceptable side effects	0	participants
Antipsychotic Efficacy, Defined as Completion of the Trial Without Psychiatric Hospitalization, Clinician Decision to Discontinue Treatment, or Patient Decision to Discontinue Treatment	Aripiprazole	Unacceptable side effects	0	participants
Antipsychotic Efficacy, Defined as Completion of the Trial Without Psychiatric Hospitalization, Clinician Decision to Discontinue Treatment, or Patient Decision to Discontinue Treatment	Olanzapine	Patient refusal	3	participants
Antipsychotic Efficacy, Defined as Completion of the Trial Without Psychiatric Hospitalization, Clinician Decision to Discontinue Treatment, or Patient Decision to Discontinue Treatment	Perphenazine	Patient refusal	0	participants
Antipsychotic Efficacy, Defined as Completion of the Trial Without Psychiatric Hospitalization, Clinician Decision to Discontinue Treatment, or Patient Decision to Discontinue Treatment	Aripiprazole	Patient refusal	0	participants

1 to 10 of 19Source ClinicalTrials.gov

See all 19 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Olanzapine	6
Overall Study	STARTED	Perphenazine	9
Overall Study	STARTED	Aripiprazole	6
Overall Study	COMPLETED	Olanzapine	0
Overall Study	COMPLETED	Perphenazine	2
Overall Study	COMPLETED	Aripiprazole	2
Overall Study	NOT COMPLETED	Olanzapine	6
Overall Study	NOT COMPLETED	Perphenazine	7
Overall Study	NOT COMPLETED	Aripiprazole	4

Source ClinicalTrials.gov

Adverse events78

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Akathisia/activation	Psychiatric disorders	Olanzapine	4	6	4
other	Akathisia/activation	Psychiatric disorders	Perphenazine	7	9	7
other	Akathisia/activation	Psychiatric disorders	Aripiprazole	6	6	6
other	Sleepiness	General disorders	Olanzapine	3	6	3
other	Sleepiness	General disorders	Perphenazine	9	9	9
other	Sleepiness	General disorders	Aripiprazole	5	6	5
other	Weight gain	General disorders	Olanzapine	3	6	3
other	Weight gain	General disorders	Perphenazine	8	9	8
other	Weight gain	General disorders	Aripiprazole	6	6	6
other	Dry mouth	General disorders	Olanzapine	3	6	3

1 to 10 of 78Source ClinicalTrials.gov

See all 78 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Olanzapine
Total, all-cause mortality	Perphenazine
Total, all-cause mortality	Aripiprazole
Total, other adverse events	Olanzapine	6	6
Total, other adverse events	Perphenazine	9	9
Total, other adverse events	Aripiprazole	6	6
Total, serious adverse events	Olanzapine	2	6
Total, serious adverse events	Perphenazine	3	9
Total, serious adverse events	Aripiprazole	3	6

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
N01MH090001	CLINICAL ANTIPSYCHOTIC TRIALS OF INTERVENTION EFFECTIVES-278990001		UNIVERSITY OF NORTH CAROLINA C	NATIONAL INSTITUTE OF MENTAL HEALTH	1989 to 2003

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00802100

GET https://conductscience.org/api/trials/v1/NCT00802100/events?page=2

API reference For AI assistants